Brixton Biosciences, a spin-out from Massachusetts General Brigham, is a clinical stage life sciences company that develops novel therapies for treating pain. Its leadership team comprises experienced managers and key medical advisors, enabling a patient-centric strategy driven by the best of the best. Backed by deep research, the company addresses crucial unmet needs in the field of pain management, which has historically been dominated by systemic medicine. Brixton Biosciences' innovative therapeutics, such as its novel Neural Ice™, provide pain relief in a single, safe, and easy drug-free injectable that is a non-addictive, locally targeted, and comparatively long-lasting solution.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/31/24 | $33,000,000 | Series B |
Catalyst Health Ventures Excelestar Ventures PV Capital Management Schooner Capital  Sparta Group SV Health Investors | undisclosed |
